Halozyme Therapeutics (HALO) Income from Continuing Operations (2010 - 2026)
Halozyme Therapeutics (HALO) reported Income from Continuing Operations of 150049000.0 for Q1 2026, up 27.06% year-over-year from 118095000.0 in Q1 2025, and up 205.97% quarter-over-quarter from 141591000.0 in Q4 2025.
Halozyme Therapeutics (HALO) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has 17 years of Income from Continuing Operations data on file, last reported at 150049000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 150049000.0, up 27.06% year-over-year; the trailing twelve-month figure through Mar 2026 was 348854000.0 (down 28.13% YoY), and the FY2025 annual result was 316889000.0, down 28.64% from the prior year.
- Income from Continuing Operations climbed to 150049000.0 in Q1 2026 per HALO's latest filing, from 141591000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 175258000.0 in Q3 2025 and troughed at 141591000.0 in Q4 2025.
- A 5-year average of 82044882.35 and a median of 81837000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2025: Income from Continuing Operations surged 229.53% in 2023, then plunged 203.34% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 57702000.0 in 2022, then surged by 47.98% to 85388000.0 in 2023, then surged by 60.46% to 137012000.0 in 2024, then sank by 203.34% to 141591000.0 in 2025, then jumped by 205.97% to 150049000.0 in 2026.
- Business Quant data shows HALO's Income from Continuing Operations at 150049000.0 in Q1 2026, 141591000.0 in Q4 2025, and 175258000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.48 Mn |
| 10 | Halozyme Therapeutics | 8.24 Bn | 7.92 Bn | 297.47 Mn | 150.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 150.05 Mn |
| Dec 31, 2025 | -141.59 Mn |
| Sep 30, 2025 | 175.26 Mn |
| Jun 30, 2025 | 165.14 Mn |
| Mar 31, 2025 | 118.10 Mn |
| Dec 31, 2024 | 137.01 Mn |
| Sep 30, 2024 | 137.01 Mn |
| Jun 30, 2024 | 93.25 Mn |
| Mar 31, 2024 | 76.82 Mn |
| Dec 31, 2023 | 85.39 Mn |
| Sep 30, 2023 | 81.84 Mn |
| Jun 30, 2023 | 74.75 Mn |
| Mar 31, 2023 | 39.62 Mn |
| Dec 31, 2022 | 57.70 Mn |
| Sep 30, 2022 | 61.63 Mn |
| Jun 30, 2022 | 22.69 Mn |
| Mar 31, 2022 | 60.11 Mn |
| Dec 31, 2021 | 66.77 Mn |
| Sep 30, 2021 | 216.59 Mn |
| Jun 30, 2021 | 91.46 Mn |